
News|Articles|February 13, 2019
Xospata for Relapsed or Refractory AML
Author(s)Drew Boxler
Advertisement
Xospata (gilteritinib, Astellas)
Indications: Adult patients with relapsed or refractor acute myeloid leukemia (AML) with an FLT3 mutation.
Dosage: 120 mg orally once-daily; 40 mg tablets
Contraindications: Hypersensitivity to gilteritinib or any of the excipients. Naphylactic reactions have been observed in clinical trials.
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Addressing Depression Symptoms Can Significantly Improve Asthma Outcomes
2
President Trump Signs Sweeping, Unprecedented Federal PBM Reform
3
What the Newest Landmark PBM Reform Means for the Pharmacy Industry
4
TrumpRx Officially Launches, Introduces Drug Prices
5























